AS1708727 is a Foxo1 inhibitor, exerting anti-hypertriglyceridemic and anti-diabetic effects by improving triglyceride and blood glucose metabolism at the gene expression level.

1253226-93-5

C24H24Cl2N2O2

443.37

AS1708727

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years